GO
Loading...

Abbott Laboratories

More

  • Jack Lew pushes for crackdown on tax inversions Wednesday, 16 Jul 2014 | 6:19 AM ET
    Jack Lew, U.S. Treasury Secretary.

    Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.

  • Yellen? Here's what traders are really focused on Tuesday, 15 Jul 2014 | 6:51 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks may respond more to earnings news than the Fed Wednesday, now that Fed Chair Janet Yellen's first day of testimony is out of the way.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, lifted by Citigroup's better-than-expected earnings and more deals in the healthcare space. Citigroup Inc shares jumped 3 percent to $48.42 and gave the S&P 500 one of its biggest boosts.

  • Stocks end higher on M&A; Dow sets intraday record Monday, 14 Jul 2014 | 4:50 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks climbed on Monday, with the S&P 500 bouncing back from weekly losses, after Citigroup's earnings beat estimates.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks rose on Monday with the Dow Jones industrial average hitting a new intraday high, lifted by better than expected earnings from Citigroup and more deals in the healthcare space.

  • July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

  • *Citigroup up after earnings, settlement. NEW YORK, July 14- U.S. stocks rose on Monday, sparked by the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on pace to climb for a second straight session.

  • Big shale deal may be easy money or strong market Monday, 14 Jul 2014 | 10:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    Big mergers are afoot. But is a major shale oil deal a sign of a strong market?

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • NEW YORK, July 14- U.S. stocks were poised for a higher open on Monday after the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on track to rebound from its worst weekly decline since April.

  • Mylan in $5.3B deal for Abbott's generics assets Monday, 14 Jul 2014 | 8:47 AM ET

    Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • *Move aimed towards making drugs more affordable in India. MUMBAI, July 14- India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • Early movers: C, AAPL, MYL, BID, EBAY, GE & more Monday, 14 Jul 2014 | 8:06 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures higher on M&A after down week Monday, 14 Jul 2014 | 7:40 AM ET

    *Shire accepts Abbvie takeover offer. *London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc, ending a long-running courtship largely motivated by tax rates. U.S.-listed shares of Shire rose 2.4 percent to $255.10 while Abbvie shed 0.7 percent to $54.56 in premarket trade.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business in developed markets outside the United States in an all-stock transaction valued at about $5.3 billion.

  • July 14- Generic drugmaker Mylan Inc said it would buy Abbott Laboratories' specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • MUMBAI, July 14- India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • Will earnings tell the story markets need to hear? Sunday, 13 Jul 2014 | 6:21 PM ET
    Traders work the floor of the New York Stock Exchange before the closing bell in New York.

    Quarterly earnings growth and clues from companies' commentaries will tell whether there really will be a bounce back in growth in the second half.

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.